Senior Complement Scientist
Achillion Pharmaceuticals, New Haven
Inspiring Science. Innovative Medicine.
Provide scientific expertise on complement to the broader organization; Conduct/guide biology studies; Work with academic collaborators.
- Provide complement expertise across Achillion functional areas, e.g., Discovery, Clinical Devevlopment, Business Development
- Play an essential role in the complement discovery program for the biology group; Design complement related experiments and work with/ internal staff/ collaboraters and CROs in executing studies
- Provide assessment and rationale in discoverying/advancing complement related compounds for new targets/new indications
- Effectively manage CROs and external consultants and collaborators
- Additional projects/responsibilities as assigned
- Work closely with Regulatory and Clinical Development groups on required regulatory filings and in support of clinical programs
- Work collaboratively within the Biology Group, including the DMPK and Toxicology groups, and across Discovery, i.e., Chemistry.
- Supervise colleagues on particular projects as needed.
- Manage study-related CROs, third party vendors, and contracts.
- Work effectively with external stakeholders, i.e.,CROs and collaborators.
Education and Experience
- Ph.D in Biology, Pharmacology, or related discipline. 5+ years experience of complement research in academic/industry setting; experience in adaptive immunity plus.
- Track record in complement research, preferably with experience in studying complement inhibitors or/and complement roles in human diseases. Broader immunology research and experience a plus. Experience in drug discovery is a plus.
Technical / Functional Skills and Knowledge
- Able to design experiments to address pharmacology effects of complement inhibitors
- Able to lead scientists/CRO to execute the experiments
- Excellent project management skills, including working on multiple projects simultaneously and the ability prioritize/multitask appropriately, are required.
- Must be able to work effectively within an interdisciplinary team setting (independently and collaboratively).
- Able to effectively communicate scientific material to multiple audiences; including technical writing and presentation.
- Demonstrated ability to influence across functions or in a matrix environment requiring strong peer relationships and to provide leadership in situations of shared accountability or high level of ambiguity.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases. Achillion’s rational, iterative approach to discovery and development has created a powerful engine for advancing novel small-molecule drugs. Achillion pairs this rigorous science with insights about patients, caregivers, and the healthcare market to choose product candidates with disruptive potential – or the potential to change treatment paradigms. This has already enabled Achillion to generate a proprietary library of over 2,000 potent and specific complement inhibitors. The company’s commitments to scientific excellence and market impact are reinforced by a culture that encourages cross-functional collaboration, organizational nimbleness and resilience, professional courage, and informed risk-taking. By combining great science, a growing commercial capability, and a keen understanding of patient needs, Achillion is rapidly becoming a fully-integrated commercial pharmaceutical company capable of bringing its factor D inhibitors to patients with rare diseases on its own. Achillion is headquartered in New Haven, Connecticut. The company’s common stock trades on the NASDAQ Global Select Market under the symbol: ACHN. Achillion is motivated to be as heroic in all of its efforts as the patients and families we are working to help, as they cope with serious diseases. Delivering on the Potential of Alternative Complement Pathway Inhibitors to Provide New Treatments for Rare Diseases and Other Serious Conditions Novel therapeutic approaches that provide potent and targeted suppression of complement, overcome the limitations of current therapy and provide for ease of administration are needed by patients who suffer from complement-mediated diseases. These patients also need improved access to additional treatment options. Achillion is currently clinical trials with ACH-4471, a first-in-class, oral complement factor D inhibitor, and anticipates advancing a next-generation factor D inhibitor, ACH-5228, into clinical development by the end of 2017. Potential indications being evaluated for Achillion’s compounds include paroxysmal nocturnal hemoglobinuria (PNH), C3 Glomerulopathy (C3G), dry age-related macular degeneration (dry AMD), and other therapeutic indications where dysregulation of the complement alternative pathway is implicated. Achillion anticipates that its platform could play a role in addressing the needs of all PNH patients, including patients who have suboptimal response to, or fail to respond to, the currently available treatment, as well as for patients suffering from other complement-mediated diseases.
Want to learn more about Achillion Pharmaceuticals? Visit Achillion Pharmaceuticals's website.
Jobs You May Like
Freelance - Terminologists (English to Vietnamese)
Unbabel, Remote - Freelance
AKQA, San Francisco
Senior Software Engineer, Security
Braintree Payments, Chicago, San Francisco, New York, Austin
Machine Learning Solution Architect
Accenture, Multiple Locations, USA
Senior Data Scientist
Drawbridge, San Mateo, CA
Analytics Co-Op Fall 2019
Cardlytics, Cardlytics - Atlanta